Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

被引：49

作者：

Gao, J. ^{[1
]}

He, Q. ^{[1
]}

Subudhi, S. ^{[1
]}

Aparicio, A. ^{[1
]}

Zurita-Saavedra, A. ^{[1
]}

Lee, D. H. ^{[1
]}

Jimenez, C. ^{[2
]}

Suarez-Almazor, M. ^{[3
]}

Sharma, P. ^{[1
,4
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA

来源：

ONCOGENE | 2015年 / 34卷 / 43期

关键词：

LYMPHOCYTE-ASSOCIATED ANTIGEN-4; DOSE-ESCALATION TRIAL; REGULATORY T-CELLS; STAGE-IV MELANOMA; METASTATIC MELANOMA; CTLA-4; BLOCKADE; AUTOIMMUNE HYPOPHYSITIS; MONOCLONAL-ANTIBODY; ANTI-CTLA-4; THERAPY;

D O I：

10.1038/onc.2015.5

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.

引用

页码：5411 / 5417

页数：7

共 41 条

[1]

Alegre ML, 1998, J IMMUNOL, V161, P3347

[2] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].

Beck, Kimberly E. ;

Blansfield, Joseph A. ;

Tran, Khoi Q. ;

Feldman, Andrew L. ;

Hughes, Marybeth S. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Topalian, Suzanne L. ;

Sherry, Richard M. ;

Kleiner, David ;

Quezado, Martha ;

Lowy, Israel ;

Yellin, Michael ;

Rosenberg, Steven A. ;

Yang, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289

[3]

Berman David, 2010, Cancer Immun, V10, P11

[4] Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for Melanoma A Case Report [J].

Bhatia, Shailender ;

Huber, Bertrand R. ;

Upton, Melissa P. ;

Thompson, John A. .

JOURNAL OF IMMUNOTHERAPY, 2009, 32 (02) :203-205

[5] Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer [J].

Blansfield, JA ;

Beck, KE ;

Tran, K ;

Yang, DC ;

Hughes, MS ;

Kammula, US ;

Royal, RE ;

Topalian, SL ;

Haworth, LR ;

Levy, C ;

Rosenberg, SA ;

Sherry, RM .

JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) :593-598

[6] Hemophilia A Induced by Ipilimumab [J].

Delyon, Julie ;

Mateus, Christine ;

Lambert, Thierry .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (18) :1747-1748

[7] Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes [J].

Dillard, Troy ;

Yedinak, Chris G. ;

Alumkal, Joshi ;

Fleseriu, Maria .

PITUITARY, 2010, 13 (01) :29-38

[8]

Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730

[9] Anti-CTLA4 Antibody-Induced Lupus Nephritis. [J].

Fadel, Fouad ;

El Karoui, Khalil ;

Knebelmann, Bertrand .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :211-212

[10] SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade [J].

Fasso, Marcella ;

Waitz, Rebecca ;

Hou, Yafei ;

Rim, Tae ;

Greenberg, Norman M. ;

Shastri, Nilabh ;

Fong, Lawrence ;

Allison, James P. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (09) :3509-3514

← 1 2 3 4 5 →